Qapzola receives setback from FDA committee

The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that   Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate in
The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate in | File photo
The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
Qapzola’s recommendation from the committee is not bound to the FDA. The FDA does, however, make the final decision when it comes to an approval for the drug.
The medication’s Prescription Drug User Fee Act date was Dec. 11.
Want to get notified whenever we write about Spectrum Pharmaceuticals, Inc. ?
Next time we write about Spectrum Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Spectrum Pharmaceuticals, Inc. 11500 S Eastern Ave Henderson, NV - 89052